Mad Hedge Technology Letter
December 8, 2021
Fiat Lux
Featured Trade:
(A HEAD-SCRATCHER IN SILICON VALLEY)
(SFIX), (AMZN)
Mad Hedge Technology Letter
December 8, 2021
Fiat Lux
Featured Trade:
(A HEAD-SCRATCHER IN SILICON VALLEY)
(SFIX), (AMZN)
I don’t get Stich Fix (SFIX).
It’s not that they shouldn’t be a company--I’ve seen worse ideas that didn’t get left on the drawing board--but I don’t see how they ever become successful.
They probably should have invested in Bitcoin at the beginning of the year.
That might be an exaggeration, but it brings home the point that their competitive advantage is marginal, and they haven’t done enough to differentiate themselves amongst competition.
For a company that is fighting for relevancy, they have made some boneheaded mistakes.
For one, customers don’t receive a great sales price on the clothes. Unless you keep the entire box (5 items), you won't get a discount. You also won't find any coupons online for Stitch Fix. You pay retail prices, which can sometimes be high, depending on the brand they send.
For many tech companies that preach the freemium model, Stich Fix is asking customers to pay a premium for the clothing off the bat, and I believe that is turning off a lot of potential customers.
SFIX hasn’t done enough to fetch a premium for its services.
I understand SFIX isn’t willing to discount any clothing, unless it’s the entire box, and this is because the unit economics of this business model is quite poor.
Revenue grew 19% year over year to $581 million, yet they forecasted just 9% revenue growth for the next quarter — that’s not what I call a tech growth company.
A tech company with only $2 billion in annual revenue shouldn’t be growing only 9% year over year. In fact, I would say a company this small needs to be accelerating revenue to somewhere around 40% to command respect among the incremental investors.
It’s no shocker that the stock is down around 300% in the past 365 days.
That’s horrible considering the “reopening trade” was supposed to cause a massive demand in people wearing proper clothes again and not just pajama pants.
To miss that opportunity epitomizes the company’s lack of marginal advantage which I was just banging on about.
Another issue I have with the company is that the clothes are not affordable, and I am not talking about a discounted price relative to the retail price.
If you are a bargain bin fanatic, the sight of SFIX’s service will turn you off.
Stitch Fix claims the average price of items is around $55, but that the items can cost anywhere between $20 and $400.
You can set price ranges for each category, but that doesn't mean your stylist will always follow those instructions.
Pigeonholing oneself as a luxury service but hoping to scale broadly and fast like a tech company is counterproductive.
Many Americans simply won’t pay up to $500 for a 5-piece set of clothing no matter who is styling it.
This sounds like a service for a computer programmer in San Francisco with a $200,000 annual salary--which isn’t a bad thing, but it won’t get the masses interested.
This leads me to my next point of the company overselling the personalized stylist aspect of it.
Is the stylist really that much better than me just picking out a few pieces at the store or online, and being able to keep it?
They even have Stitch Fix “Freestyle” category now that is SFIX without the styling fee, where the customer can personally choose their clothes. But then, isn’t that the same as any other online retailer but with higher price?
Again, I don’t get the roadmap here and it’s basically admitting that their styling is not good.
In fact, there is quite robust competition that undercuts SFIX such as Amazon (AMZN) Prime Wardrobe.
Amazon Prime Wardrobe is an exclusive program just for Prime members. This service gives users the chance to have chosen clothing items shipped to their home for them to try on before buying. The difference here is that the user selects the item which, for me at least, makes sense instead of SFIX blindly shipping clothes that aren’t ok’d. I just don’t think a “stylist” can get it right more than half the time. You only pay for what you keep and you have 7 days to make up your mind.
The biggest headscratcher is the $20 SFIX styling fee if you don't keep anything.
Seriously, what is that about?
If you hate their expert stylish decisions, you get blamed for it and pay $20 for nothing! Shouldn’t it be SFIX paying the user $20 for failed style sense?
Any person with a brain understands that paying $20 just to try something on then sending it back sounds like the worst way to convince someone to become a long-term customer.
And this is without even mentioning the pain of resending the clothes!
So, in an era where software companies have made software as a subscription (SaaS) almost a religion, there is no subscription service for SFIX.
This means there is a high number of churn where customers use their service once then never again, most likely after they are charged $20 to try on clothes they don’t like and have to send back the failed styled clothing.
Marginally, this company doesn’t cut it, we will check in with the next iteration of SFIX sometime in the future, but in it its current form, the 300% drawdown in the stock is absolutely logical.
“Often you have to rely on intuition.” – Said Founder and Former CEO of Microsoft Bill Gates
Global Market Comments
December 8, 2021
Fiat Lux
Featured Trade:
(ON EXECUTING MY TRADE ALERTS),
(TEN REASONS WHY STOCKS CAN’T SELL OFF BIG TIME),
(SPY), (INDU), ($COMPQ), (IWM), (TLT), (GME)
Mad Hedge Biotech and Healthcare Letter
December 7, 2021
Fiat Lux
Featured Trade:
(GET READY FOR THE SECOND WAVE OF COVID-19 VACCINES)
(NVAX), (MRNA), (PFE), (BNTX), (JNJ), (AZN), (SNY)
Moderna (MRNA) and Pfizer (PFE) / BioNTech (BNTX) unquestionably rule the COVID-19 vaccine market these days.
These companies have amassed billions in quarterly revenue from their vaccine candidates, with Moderna expecting $18 billion and Pfizer/BioNTech anticipating $36 billion in annual sales this year.
Other than these two, Johnson & Johnson (JNJ) and AstraZeneca (AZN) offer COVID-19 vaccines, but these appear to be distant rivals to the mRNA contenders.
However, it looks like the COVID-19 vaccine market will soon get another competitor—one that has a solid potential to truly carve out a considerable share: Novavax (NVAX).
At this point, Novavax’s vaccine candidate has yet to gain authorization in major markets.
Its shares have also fallen by over 30% since it started in January this year. Nonetheless, the company is projected to turn things around starting this December.
For one, it has already started filing for regulatory approval in various countries and recently gained authorization in Indonesia and the Philippines. Meanwhile, it plans to file for approval in the US before 2021 ends.
To date, Novavax has secured $7 billion worth of advance purchase agreements for its vaccine by 2022.
But a more promising catalyst for Novavax lies in its proven technology.
This makes it notably distinct from Moderna and Pfizer’s vaccines. Simply put, Novavax isn’t offering new technology like the mRNA vaccine.
Rather, Novavax uses a tried and tested approach in the form of protein subunit vaccines. These constitute the very same technology used in vaccines that have been long available in markets, such as the Hepatitis B vaccine.
Considering the pushback in using new technology like mRNA, which comes from healthcare professionals and patients, the entry of a long-established vaccine technology would encourage more people to get the coronavirus jab.
Moreover, Novavax’s candidate can be stored at refrigerator temperatures. This is more convenient compared to the vaccines of Moderna and Pfizer, which require freezer temperatures.
The latest coronavirus variant, Omicron, brings about another catalyst.
Since the WHO announced Omicron’s presence last month, the entire world, including the stock market, has been rattled.
However, this announcement also served to light a fire under COVID-19 vaccine stocks.
After all, every problem can offer an opportunity. Omicron’s emergence has boosted the demand for COVID-19 vaccines.
While it’s never advisable to get the cart ahead of the horse, especially since the worries over the Omicron might be premature, it’s still reasonable to assume that the anxiety triggered by the news will most likely increase the popularity of vaccine stocks.
In the case of Novavax, the company is taking advantage of this exposure to announce that it is currently working on a candidate that’s potent against the new variant.
Beyond Novavax’s COVID-19 vaccine, the company has 8 more programs queued in its pipeline. Of these, 3 are in Phase 2/3 clinical trials.
These include ResVax and RSV F, which are vaccines against the respiratory syncytial virus (RSV). While adults can recover from RSV within weeks, this virus can be fatal to infants and children.
The most promising candidate is NanoFlu, which received a Fast Track Designation from the US FDA in early 2020. It also recorded top-line data against Fluzone from Sanofi (SNY), the leading flu vaccine today.
To give an idea of NanoFlu’s potential, Fluzone raked in $2.9 billion in sales in 2020—and it hasn’t even covered most of the market yet.
Considering NanoFlu’s Phase 3 clinical trials results, the product is estimated to generate more than $9.5 billion in global revenue by 2027.
Admittedly, Novavax investors have experienced a bumpy ride throughout 2021. However, it appears that the biotechnology company is on its way up, thanks to a couple of catalysts that lie ahead.
While I still think that Moderna and Pfizer are great stocks for long-term investments, these companies have already reaped the benefits of share performance. It may very well be Novavax’s turn to impress the market in the next few weeks.
Mad Hedge Bitcoin Letter
December 7, 2021
Fiat Lux
Featured Trade:
(THE BITCOIN BULL STORY IS IN-TACT)
(BTC), (ADA), (ETH)
No, the Bitcoin bull market is not over, but we won’t get our Santa Claus rally this year.
The short-term reversal in prices has been encouraging, but I do expect further bouts of volatility to occur most likely in early January.
We received some great signaling that capital isn’t bolting out the back of the stable with Bitcoin returning to over $50,000 overnight inspired by one of the largest wallets to buy the equivalent of $137 million more Bitcoin.
This Bitcoin whale is loading up again here, even though so many people and fake bitcoin keyboard warriors are saying that we are now in a bear market.
I don't see any confirmation of the bear market yet as no key support has been lost.
This wallet holder upped the ante overnight with a single purchase of 2,700 BTC — taking their total to 118,017 BTC.
The buy crushes previous recent transactions and increases the holder’s balance to breathtaking record levels.
This is officially the highest number of BTC ever held in this wallet: 118,017 BTC, in total this big spender has poured $2.5B USD to buy BTC with an average cost basis of $21,160 per BTC.
Interest and demand in Bitcoin rose a lot in 2021 despite the volatility. More than half of current investors got in over the last 12 months, adding another positive data point to the Bitcoin narrative.
In a survey of 1,000 people, about a quarter said they already owned Bitcoin and of that 55% said they started investing this year.
The results highlight the explosive growth cryptocurrencies have seen this year as investors plowed money toward the volatile asset class amid growing mainstream adoption.
It is becoming increasingly difficult for investors to ignore Bitcoin as its price continues to rise.
Major altcoins have also reversed course with this relief rally.
Ether (ETH) rallied 11.4% Tuesday, outpacing BTC in a pattern mimicked by several other large-cap tokens.
Other altcoins like Cardano (ADA) and Litecoin are up over 9% validating my thesis of altcoins outgaining Bitcoin for the catch-up trade.
I don’t believe that this weekend's crash can partially be blamed on the US congress' upcoming questioning of top crypto executives. Nobody knows yet how badly this investigation will impact the market, but I wouldn’t say anything meaningful will happen.
In fact, much of the volatility has been caused by poor communication from the US Central Bank that peaked with US Fed Chair Jerome Powell signaling the Fed will move faster than expected to tame inflation.
The algorithms had a field day dumping positions in volume.
Consensus had it that interest rate expectations would largely be left alone this December, but the Fed signaling that they plan to move earlier to break off the inflation genie caused all risk assets into a short-term tailspin.
That being said, I don’t believe the Fed will do more damage the rest of this month, and we should experience a relief rally into the yearend.
I would double down and say the Fed could have waited until January, because everyone understands how bad inflation is running its course, and it was largely baked into the market.
To get ahead of the next CPI inflation number is definitely a knee-jerk reaction and if the Fed has more of these fast pivots in 2022, we will experience a 10-15% correction in Bitcoin each time.
Long term, the US financial system will not be able to stave off highly inflationary policies, it’s like a drug addiction that can’t be shaken off.
Triggering inflationary-backed economic growth is the only way to make a dent in the federal debt hole, it just means that home price and wages will be a lot higher in nominal terms every year.
I merely see this short-term swoon as one step backward before we push forward again with the wild inflation.
People in the know have acknowledged that many corporations are building up reserves for 30% increases for 2022 salary and that is not a typo.
“I wished it had never been invented” – Said Billionaire Investors Charlie Munger when asked about Bitcoin
Global Market Comments
December 7, 2021
Fiat Lux
Featured Trade:
(GET READY TO TAKE A LEAP BACK INTO LEAPS),
(AAPL), (BRK/B)
(TESTIMONIAL)
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.